Top

Published in:

01-08-2009 | Gastrointestinal Oncology

A Prospective Trial Comparing 1% Lymphazurin vs 1% Methylene Blue in Sentinel Lymph Node Mapping of Gastrointestinal Tumors

Authors: Mehul Soni, MD, Sukamal Saha, MD, FACS, FRCS(C), Alpesh Korant, MD, Patti Fritz, CRNA, Bishan Chakravarty, MD, Saad Sirop, MD, Adam Gayar, Douglas Iddings, DO, David Wiese, MD

Published in: Annals of Surgical Oncology | Issue 8/2009

Abstract

Background

Methylene blue (M), as a dye in sentinel lymph node mapping (SLNM), has been introduced as an alternative to lymphazurin (L) after the recent shortage of L. M has been evaluated in breast cancer in multiple studies with favorable results. Our study compares L with M in the SLNM of gastrointestinal (GI) tumors.

Methods

Between Jan 2005 and Aug 2008, 122 consecutive patients with GI tumors were enrolled. All patients (pts) underwent SLNM with either L or M by subserosal injection of 2–5 mL of dye. Efficacy and rates of adverse reactions were compared between the two dyes. Patients were prospectively monitored for adverse reactions including anaphylaxis, development of blue hives, and tissue necrosis.

Results

Of 122 pts, 60 (49.2%) underwent SLNM using L and 62 (50.8%) underwent SLNM using M. Colon cancer (CrCa) was the most common site in both groups. The success rate of L and M in SLNM was 96.6% and 96.7%, respectively, with similar numbers of total number of lymph nodes per pt, SLNs per pt (<3), nodal positivity, skip metastasis, and accuracy. The only adverse reaction in the L group was oxygen desaturation >5% in 5% (3/60) of pts, compared with none in the M group. Cost per vial of L was $210 vs $7 for M.

Conclusion

The success rate, nodal positivity, average SLNs per patient, and overall accuracy were similar between L and M. Absence of anaphylaxis and lower cost make M more desirable than L in SLNM of GI tumors.

Cabanas RM. An approach for the treatment of penile carcinoma. Cancer. 1977;39:456–6.PubMedCrossRef

Morton DL, Wen DR, Wong JH, Economou JS, Cagle LA, Storm FK, et al. Technical details of intraoperative lymphatic mapping for early stage melanoma. Arch Surg. 1992;127:392–9.PubMed

Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg. 1994;220:391–8; discussion 398–401.PubMedCrossRef

Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol. 1997;15:2345–50.PubMed

Tsoulias GJ, Wood TF, Morton DL, Bilchik AJ. Lymphatic mapping and focused analysis of sentinel lymph nodes upstage gastrointestinal neoplasms. Arch Surg. 2000;135:926–32.CrossRef

Saha S, Dan AG, Bilchik AJ, Kitagawa Y, Schochet E, Choudhri S, et al. Historical review of lymphatic mapping in gastrointestinal malignancies. Ann Surg Oncol. 2004;11:245S–9S.PubMedCrossRef

Burian, M, Stein HJ, Sendler A, Piert M, Nährig J, Feith M, et al. Sentinel node detection in Barrett’s and Cardia cancer. Ann Surg Oncol. 2004;11:255S–8S.PubMed

Saha S, Ganatra BK, Gauthier J, et al. Localization of sentinel lymph node in colon cancer. A feasibility study. In Society of Surgical Oncology 50th Annual Cancer Symposium. vol. 54, 1997. p. 80.

Saha S, Dan AG, Berman B, Wiese D, Schochet E, Barber K, et al. Lymphazurin 1% versus 99mTc sulfur colloid for lymphatic mapping in colorectal tumors: A comparative analysis. Ann Surg Oncol. 2004;11:21–6.PubMedCrossRef

10.

Dan AG, Saha S, Monson KM, Wiese D, Schochet E, Barber KR, et al. 1% lymphazurin vs 10% fluorescein for sentinel node mapping in colorectal tumors Arch Surg. 2004;139:1180–4.PubMedCrossRef

11.

Saha S, Seghal R, Patel M, Doan K, Dan A, Bilchik A, et al. A multicenter trial of sentinel lymph node mapping in colorectal cancer: prognostic implications for nodal staging and recurrence. Am J Surg. 2006;191:305–10.PubMedCrossRef

12.

Kitagawa Y, Saha S, Kubo A, Kitajima M. Sentinel node for gastrointestinal malignancies. Surg Oncol Clin N Am. 2007;16:71–80.PubMedCrossRef

13.

Levenback CF. Status of sentinel lymph node biopsy in gynecological cancers. Surg Oncol. 2008;15:18–20.CrossRef

14.

Simmons R, Thevarajah S, Brennan MB, Christos P, Osborne M. Methylene blue dye as an alternative to isosulfan blue dye for sentinel lymph node localization. Ann Surg Oncol. 2003;10:242–7.PubMedCrossRef

15.

Sandhu, S, Farag E, Argalious, M. Anaphylaxis to isosulfan blue dye during sentinel lymph node biopsy. J Clin Anesth. 2005;17:633–5.PubMedCrossRef

16.

Thevarajah S, Huston TL, Simmons RM. A comparison of the adverse reactions associated with isosulfan blue versus methylene blue dye in sentinel lymph node biopsy for breast cancer. Am J Surg. 2005;189:236–9.PubMedCrossRef

17.

Leong SP, Donegan E, Heffernon W, Dean S, Katz JA. Adverse reactions to isosulfan blue during selective sentinel lymph node dissection in melanoma. Ann Surg Oncol. 2000;7:361–6.PubMedCrossRef

18.

Kaufman, G, Guth AA, Pachter HL, Roses DF. A cautionary tale: Anaphylaxis to isosulfan blue dye after 12 years and 3339 cases of lymphatic mapping. Am Surg. 2008;74:2.

19.

Dewachter P, Mouton-Faivre C, Tréchot P, Lleu JC, Mertes PM. Severe anaphylactic shock with methylene blue instillation. Anesth Analg. 2005;101:149–50.PubMedCrossRef

20.

Millo T, Misra R, Girdhar S, Rautji R, Lalwani S, Dogra TD. Fatal pulmonary edema following laparascopic chromopertubation. Natl Med J India. 2006;19:78–9.PubMed

21.

Saha S, Dan AG, Viehl CT, Zuber M, Wiese D. Sentinel lymph node mapping in colon and rectal cancer: Its impact on staging, limitations, and pitfalls. Cancer Treat Res. 2005;127:105–22.PubMedCrossRef

22.

Momeni R, Ariyan S. Pulse oximetry declines due to intradermal isosulfan blue dye: A controlled prospective study. Ann Surg Oncol. 2004;11:434–7.PubMedCrossRef

23.

Morell, R, Heyneker T, Kashtan HI, Ruppe C. False desaturation due to intradermal patent blue dye. Anesthesiology. 1993;78:363–4.PubMedCrossRef

24.

Vokach-Brodsky L, Jeffrey SS, Lemmens HJ, Brock-Utne JG. Isosulfan blue affects pulse oximetry. Anesthesiology. 2000;93:1002–3.PubMedCrossRef

25.

Vieira SC, Sousa RB, Tavares MB, de Abreu BA, Ibiapina JO, de Sousa Oliveira AK, et al. Changes in pulse oximetry after patent blue dye injection into uterine the uterine cervix. Ann Surg Oncol. 2008;15:2862–6.PubMedCrossRef

Title: A Prospective Trial Comparing 1% Lymphazurin vs 1% Methylene Blue in Sentinel Lymph Node Mapping of Gastrointestinal Tumors
Authors: Mehul Soni, MD
Sukamal Saha, MD, FACS, FRCS(C)
Alpesh Korant, MD
Patti Fritz, CRNA
Bishan Chakravarty, MD
Saad Sirop, MD
Adam Gayar
Douglas Iddings, DO
David Wiese, MD
Publication date: 01-08-2009
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 8/2009
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-009-0529-y

Keynote webinar | Spotlight on medication adherence

Springer Medicine

A Prospective Trial Comparing 1% Lymphazurin vs 1% Methylene Blue in Sentinel Lymph Node Mapping of Gastrointestinal Tumors

Abstract

Background

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 8/2009

Colorectal Cancer Screening Among First-Degree Relatives of Colorectal Cancer Patients: Benefits and Barriers

Incidence, Risk Factors, and Impact of Severe Neutropenia After Hyperthermic Intraperitoneal Mitomycin C

Response to Letter to the Editor: Postoperative Infectious Morbidity for Resectable Gastric Cancer: Searching Robust Predictors of Survival

A Systematic Review and Meta-Analysis of Cytoreductive Surgery with Perioperative Intraperitoneal Chemotherapy for Peritoneal Carcinomatosis of Colorectal Origin

Clinical Significance of Microvessel Count in Patients with Metastatic Liver Cancer Originating from Colorectal Carcinoma

False-Negative Sentinel Node Biopsy